, Volume 31, Issue 8, pp 703–718 | Cite as

Real-World Cost-Effectiveness of Oxaliplatin in Stage III Colon Cancer: A Synthesis of Clinical Trial and Daily Practice Evidence

  • Chantal W. M. van Gils
  • Saskia de Groot
  • William K. Redekop
  • Miriam Koopman
  • Cornelis J. A. Punt
  • Carin A. Uyl-de Groot
Original Research Article



Previous cost-effectiveness analyses of oxaliplatin have been based on randomised trials whereas current Dutch policy requires evidence from daily practice. The objective of this study was to examine the real-world cost-effectiveness of oxaliplatin plus fluoropyrimidines (FL) versus FL-only as adjuvant treatment of stage III colon cancer.


A Markov model was developed to estimate lifetime cost and quality-adjusted life-years from a hospital perspective. The effectiveness of the oxaliplatin arm was modelled by combining published efficacy data from the pivotal clinical registration trial (MOSAIC trial) with real-world (RW) data from a Dutch population-based observational study. RW patients were categorised into “eligible” or “ineligible”, depending on whether the patients fulfilled the MOSAIC trial eligibility criteria. Ineligible RW patients (18 %) had a poorer prognosis than eligible RW patients (82 %) and MOSAIC trial patients. The effectiveness of the comparator was modelled using MOSAIC trial results. All cost inputs were based on RW patients and reported in Euro 2012. Cost-effectiveness analyses were performed for four different scenarios: (1) cost-effectiveness analyses based on MOSAIC trial patients; (2) cost-effectiveness analyses using MOSAIC and eligible RW patients; (3) cost-effectiveness analyses using MOSAIC and both eligible and ineligible RW patients, assuming oxaliplatin had an equal effect in ineligible and eligible patients; (4) cost-effectiveness analyses using MOSAIC and both eligible and ineligible RW patients, assuming oxaliplatin had no effect amongst ineligibles. For each scenario, univariate and probabilistic sensitivity analyses were undertaken.


MOSAIC trial patients and eligible RW patients treated with oxaliplatin had comparable 2-year disease-free survivals (79.5 vs. 78.4 %). Oxaliplatin showed an incremental QALY gain of 1.02, 1.13, 1.17 and 0.93 and incremental cost of €9,961, €11,055, €9,814 and €11,854 in scenarios 1–4, respectively. The corresponding incremental cost-effectiveness ratios (ICERs) were €9,766, €9,783, €8,388 and €12,746 in scenarios 1–4, respectively. In all scenarios, univariate and probabilistic sensitivity analyses indicated that the ICERs are acceptable and robust under a wide range of model assumptions.


The ICERs of the different scenarios that resulted from combining MOSAIC trial data with data from Dutch daily practice all suggest that FL + oxaliplatin is cost-effective versus FL alone in the adjuvant treatment of colon cancer. This article illustrates how one could design and implement a real-world cost-effectiveness study to yield internally valid results that could also be generalisable.

Supplementary material

40273_2013_61_MOESM1_ESM.docx (31 kb)
Supplementary material 1 (DOCX 30 kb)
40273_2013_61_MOESM2_ESM.docx (25 kb)
Supplementary material 2 (DOCX 25 kb)


  1. 1.
    Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013.Google Scholar
  2. 2.
    Obrand DI, Gordon PH. Incidence and patterns of recurrence following curative resection for colorectal carcinoma. Dis Colon Rectum. 1997;40(1):15–24.CrossRefPubMedGoogle Scholar
  3. 3.
    Labianca R, Marsoni S, Pancera G, Torri V, Zaniboni A, Erlichman C, et al. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet. 1995;345(8955):939–44.CrossRefGoogle Scholar
  4. 4.
    Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Goodman PJ, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 1990;322(6):352–8.CrossRefPubMedGoogle Scholar
  5. 5.
    Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350(23):2343–51.CrossRefPubMedGoogle Scholar
  6. 6.
    Cassidy J, Tabernero J, Twelves C, Brunet R, Butts C, Conroy T, et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol. 2004;22(11):2084–91.CrossRefPubMedGoogle Scholar
  7. 7.
    Shields AF, Zalupski MM, Marshall JL, Meropol NJ. Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabine: a phase II trial. Cancer. 2004;100(3):531–7.CrossRefPubMedGoogle Scholar
  8. 8.
    Punt CJ. Chemotherapy of patients with colorectal carcinoma. Ned Tijdschr Geneeskd. 2005;149(26):1441–7.PubMedGoogle Scholar
  9. 9.
    Twelves C, Wong A, Nowacki MP, Abt M, Burris H 3rd, Carrato A, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med. 2005;352(26):2696–704.CrossRefPubMedGoogle Scholar
  10. 10.
    Dewel G. Guidance for outcomes research [Leidraad voor uitkomstenonderzoek]. Diemen: College voor Zorgverzekeringen; 2008. Report no. 270.Google Scholar
  11. 11.
    Kuijpers M, Toenders W. Assessment procedure for inpatient drugs (Procedure beoordeling intramurale geneesmiddelen). Diemen: College voor Zorgverzekeringen; 2006. Report no. 26022597.Google Scholar
  12. 12.
    Aballea S, Boler A, Craig A, Wasan H. An economic evaluation of oxaliplatin for the adjuvant treatment of colon cancer in the United Kingdom (UK). Eur J Cancer. 2007;43(11):1687–93.CrossRefPubMedGoogle Scholar
  13. 13.
    Aballea S, Chancellor JV, Raikou M, Drummond MF, Weinstein MC, Jourdan S, et al. Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US. Cancer. 2007;109(6):1082–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Attard CL, Maroun JA, Alloul K, Grima DT, Bernard LM. Cost-effectiveness of oxaliplatin in the adjuvant treatment of colon cancer in Canada. Curr Oncol. 2010;17(1):17–24.PubMedGoogle Scholar
  15. 15.
    Shiroiwa T, Takeuchi T, Fukuda T, Shimozuma K, Ohashi Y. Cost-effectiveness of adjuvant FOLFOX therapy for stage III colon cancer in Japan based on the MOSAIC trial. Value Health. 2012;15(2):255–60.CrossRefPubMedGoogle Scholar
  16. 16.
    Eggington S, Tappenden P, Pandor A, Paisley S, Saunders M, Seymour M, et al. Cost-effectiveness of oxaliplatin and capecitabine in the adjuvant treatment of stage III colon cancer. Br J Cancer. 2006;95(9):1195–201.CrossRefPubMedGoogle Scholar
  17. 17.
    Rothwell PM. External validity of randomised controlled trials: “to whom do the results of this trial apply?”. Lancet. 2005;365(9453):82–93.CrossRefPubMedGoogle Scholar
  18. 18.
    van Gils CW, Koopman M, Mol L, Redekop WK, Uyl-de Groot CA, Punt CJ. Adjuvant chemotherapy in stage III colon cancer: guideline implementation, patterns of use and outcomes in daily practice in The Netherlands. Acta Oncol. 2012;51(1):57–64.CrossRefPubMedGoogle Scholar
  19. 19.
    Andre T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC Trial. J Clin Oncol. 2009;27(19):3109–16.CrossRefPubMedGoogle Scholar
  20. 20.
    van Gils CWM, Redekop WK, de Groot S, Tan SS, Koopman M, Mol L, et al. Pilot outcomes research: costs and effects of oxaliplatin in stage III and metastatic colorectal cancer. 2010.
  21. 21.
    Thirunavukarasu P, Sukumar S, Sathaiah M, Mahan M, Pragatheeshwar KD, Pingpank JF, et al. C-stage in colon cancer: implications of carcinoembryonic antigen biomarker in staging, prognosis, and management. J Natl Cancer Inst. 2011;103(8):689–97.CrossRefPubMedGoogle Scholar
  22. 22.
    Pandor A, Eggington S, Paisley S, Tappenden P, Sutcliffe P. The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation. Health Technol Assess 2006;10(41):iii–iv, xi–xiv, 1–185.Google Scholar
  23. 23.
    Rodenburg-van Dieten HEM. Richtlijnen voor farmaco-economisch onderzoek; evaluatie en actualisatie; 2005.Google Scholar
  24. 24.
    Centraal Bureau voor de Statistiek.
  25. 25.
    Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Introduction to meta-analysis. New York: Wiley; 2009.Google Scholar
  26. 26.
    Ness RM, Holmes AM, Klein R, Dittus R. Utility valuations for outcome states of colorectal cancer. Am J Gastroenterol. 1999;94(6):1650–7.CrossRefPubMedGoogle Scholar
  27. 27.
    Ramsey SD, Andersen MR, Etzioni R, Moinpour C, Peacock S, Potosky A, et al. Quality of life in survivors of colorectal carcinoma. Cancer. 2000;88(6):1294–303.CrossRefPubMedGoogle Scholar
  28. 28.
    Tan SS, Hakkaart-van Roijen L, Al MJ, Bouwmans CA, Hoogendoorn ME, Spronk PE, et al. A microcosting study of intensive care unit stay in the Netherlands. J Intensive Care Med. 2008;23(4):250–7.CrossRefPubMedGoogle Scholar
  29. 29.
    Tan SS, Van Gils CW, Franken MG, Hakkaart-van Roijen L, Uyl-de Groot CA. The unit costs of inpatient hospital days, outpatient visits, and daycare treatments in the fields of oncology and hematology. Value Health. 2010;13(6):712–9.CrossRefPubMedGoogle Scholar
  30. 30.
    Nederlandse Zorg autoriteit (The Dutch Healthcare Authority). 2009.
  31. 31.
    Pharmacotherapeutical Aid Committee (CFH), Health Care Insurance Board (CVZ). 2009.
  32. 32.
    Statistics Netherlands. 2009.
  33. 33.
    Richtlijnen oncologische zorg.
  34. 34.
    Punt CJ. New options and old dilemmas in the treatment of patients with advanced colorectal cancer. Ann Oncol. 2004;15(10):1453–9.CrossRefPubMedGoogle Scholar
  35. 35.
    Tournigand C, Andre T, Bonnetain F, Chibaudel B, Lledo G, Hickish T, et al. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial. J Clin Oncol. 2012;30(27):3353–60.CrossRefPubMedGoogle Scholar
  36. 36.
    Franken MG, van Gils CW, Gaultney JG, Delwel GO, Goettsch W, Huijgens PC, et al. Practical feasibility of outcomes research in oncology: lessons learned in assessing drug use and cost-effectiveness in The Netherlands. Eur J Cancer. 2013;49(1):8–16.CrossRefPubMedGoogle Scholar
  37. 37.
    Kuebler JP, Wieand HS, O’Connell MJ, Smith RE, Colangelo LH, Yothers G, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol. 2007;25(16):2198–204.CrossRefPubMedGoogle Scholar
  38. 38.
    Haller DG, Cassidy J, Tabernero J, et al. Efficacy findings from a randomized phase III trial of capecitabine plus oxaliplatin versus bolus 5-FU/LV for stage III colon cancer (NO16968): no impact of age on disease-free survival (DFS) (abstract). Presented at the 2010 ASCO gastrointestinal cancers symposium, Orlando, 22 January 2010.Google Scholar
  39. 39.
    Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen CM, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med. 1995;122(5):321–6.CrossRefPubMedGoogle Scholar
  40. 40.
    Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med. 2009;360(6):563–72.CrossRefPubMedGoogle Scholar
  41. 41.
    Petrou S, Campbell N. Stabilisation in colorectal cancer. Int J Palliat Nurs. 1997;3:275–80.Google Scholar

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  • Chantal W. M. van Gils
    • 1
  • Saskia de Groot
    • 1
  • William K. Redekop
    • 1
  • Miriam Koopman
    • 2
  • Cornelis J. A. Punt
    • 3
  • Carin A. Uyl-de Groot
    • 1
  1. 1.Department of Health Policy and Management, Institute for Medical Technology AssessmentErasmus UniversityRotterdamThe Netherlands
  2. 2.Department of Medical OncologyUniversity Medical CentreUtrechtThe Netherlands
  3. 3.Department of Medical Oncology, Academic Medical CentreUniversity of AmsterdamAmsterdamThe Netherlands

Personalised recommendations